
Browsing restrictions can be lifted for a fee.
TaiDoc Technology Corporation manufactures and markets medical devices worldwide. It offers In vitro diagnostics products, including blood glucose and multiple parameters monitoring systems, point of care testing devices, lancet and lancing devices, and vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. The company also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, it offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.
4736
泰博
-2.01%
(-0.02)
The most recent financial report for 泰博 (4736) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4736's short-term business performance and financial health. For the latest updates on 4736's earnings releases, visit this page regularly.
According to historical valuation range analysis, 泰博 (4736)'s current price-to-earnings (P/E) ratio is 9.95, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 泰博 (4736) reported an Operating Profit of 158.01M with an Operating Margin of 14.66% this period, representing a decline of 49.32% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 泰博 (4736) announced revenue of 1.08B, with a Year-Over-Year growth rate of -12.5%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 泰博 (4736) held Total Cash and Cash Equivalents of 2.12B, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 泰博 (4736) achieved the “three margins increasing” benchmark, with a gross margin of 39.84%%, operating margin of 14.66%%, and net margin of 58.62%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4736's profit trajectory and future growth potential.
According to the past four quarterly reports, 泰博 (4736)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 6.43. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
泰博 (4736)'s Free Cash Flow (FCF) for the period is 68.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 277.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.